GLP ‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes
Authors' conclusion
Current real-world evidence suggests that GLP-1-based therapies in T1D may provide clinically meaningful CV and renal benefits with a reassuring safety profile; however, adequately powered randomised trials are needed to confirm these findings.
Study context
- Population
- Adults with T1D3 observational studies
- Comparison
- GLP-1-based therapies in T1D
- Outcome
- CV, clinical and renal outcomes
Main finding
As reported in the abstract
- Clinically meaningful reductions in all-cause mortality, hospitalisation, HF and composite cardiovascular (CV) outcomes
- Lower risks of early eGFR decline and end-stage kidney disease
- Evidence entirely observational
Safety
DKA and severe hypoglycaemia
- No consistent increase in DKA or severe hypoglycemia
Original publication
GLP ‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes. Diabetes Obes Metab. Published 30 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →